Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19
Immune-mediated rheumatic diseases (IMRDs), based on the leading mechanisms of pathogenesis, are conditionally classified into autoimmune, autoinflammatory, and «mixed pattern». In the spectrum of cytokines involved in the development of the immunopathological process in IMRDs, the “pro-inflammatory...
Main Authors: | E. L. Nasonov, A. S. Avdeeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2022-05-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3153 |
Similar Items
-
B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
by: E. L. Nasonov, et al.
Published: (2021-09-01) -
Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity
by: E. L. Nasonov, et al.
Published: (2020-09-01) -
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
by: E. L. Nasonov, et al.
Published: (2021-07-01) -
Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force
by: Anna Carolina Faria Moreira Gomes Tavares, et al.
Published: (2022-01-01) -
EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)
by: E. L. Nasonov, et al.
Published: (2020-04-01)